Earnings per Share (EPS) of $0.01 was reported, falling below the estimated $0.08.Record quarterly service revenue of $14.9 million in Q2 2026, marking an 11% increase in total revenue to $15 million.Oncology services segment reported a profit of $7.8 million, with a margin of 52%, indicating strong performance.Champions Oncology, Inc. (NASDAQ:CSBR) is a key player in the field of translational oncology research. The company specializes in providing comprehensive research and development solutions to biopha ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Champions Oncology (NasdaqCM:CSBR) Q2 2026 Earnings Call December 15, 2025 04:30 PM ET Company ParticipantsRob Brainin - CEODavid Miller - CFOConference Call ParticipantsMatt Hewitt - Semior Research AnalystNone - AnalystOperatorPlease note, this conference is being recorded. I will now turn the conference over to your host, Rob Brainen, Chief Executive Officer. You may begin.Rob BraininGood afternoon, and thank you for participating in our second quarter fiscal 2026 earnings call. I'm joined today by our C ...

Champions Oncology (NasdaqCM:CSBR) Q2 2026 Earnings Call December 15, 2025 04:30 PM ET Company ParticipantsRob Brainin - CEODavid Miller - CFOConference Call ParticipantsMatt Hewitt - Senior Research AnalystNone - AnalystOperatorPlease note, this conference is being recorded. I will now turn the conference over to your host, Rob Brainin, Chief Executive Officer. You may begin.Rob BraininGood afternoon, and thank you for participating in our 2nd Quarter Fiscal 2026 Earnings Call. I'm joined today by our CFO, ...

Champions Oncology (NasdaqCM:CSBR) Q2 2026 Earnings Call December 15, 2025 04:30 PM ET Speaker0Please note, this conference is being recorded. I will now turn the conference over to your host, Rob Brainen, Chief Executive Officer. You may begin.Speaker1Good afternoon, and thank you for participating in our second quarter fiscal 2026 earnings call. I'm joined today by our CFO, David Miller. Before we begin, I'll remind you that today's remarks may include forward-looking statements. Actual results may differ ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. For the quarterly period ended October 31, 2025 Or (Exact name of registrant as defined in its charter) (Former name, former address and former fiscal year, if chan ...

Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal year Hackensack, NJ – December 15, 2025 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading translational oncology research organization, today announced its financial results for its second quarter of fiscal 2026, ended October ...

公司财务与运营信息披露 - 公司为领先的转化肿瘤学研究机构，将于2025年12月15日（星期一）市场收盘后，发布截至2025年10月31日的2025财年第二季度财务和运营业绩 [1] - 公司计划在业绩发布当天下午4:30举行电话会议，讨论相关业绩结果 [1]

盘前交易概况 - 美国东部时间周五上午7:45盘前交易出现显著活动 多个股票出现早期价格变动信号 预示开盘前存在潜在机会[1] - 盘前交易为活跃交易者提供识别潜在突破 反转或剧烈价格波动的先发优势 这些早期动向通常预示常规交易时段的动量走向[1] 盘前涨幅领先股票 - AGM Group Holdings Inc (AGMH) 上涨185%至6.36美元 位列涨幅榜首[3] - AlphaVest Acquisition Corp (ATMV) 上涨77%至26.80美元 涨幅排名第二[3] - Brera Holdings PLC (BREA) 上涨20%至30.00美元 涨幅排名第三[3] - Asset Entities Inc (ASST) 和22nd Century Group Inc (XXII) 均上涨18% 分别报4.54美元和2.08美元[3] - Millennium Group International Holdings Limited (MGIH) 上涨16%至2.84美元[3] - Robo.ai Inc (AIIO) 上涨11%至2.17美元 Butterfly Network Inc (BFLY) 上涨10%至2.10美元[3] - GrafTech International Ltd (EAF) 上涨9%至13.91美元 Cardlytics Inc (CDLX) 上涨8%至2.99美元[3] 盘前跌幅领先股票 - ECD Automotive Design Inc (ECDA) 下跌14%至3.70美元 位列跌幅榜首[4] - Champions Oncology Inc (CSBR) Beam Global (BEEM) 和Fathom Holdings Inc (FTHM) 均下跌8% 分别报6.11美元 2.79美元和2.19美元[4] - Ventyx Biosciences Inc (VTYX) 下跌7%至2.20美元[4] - SciSparc Ltd (SPRC) Lightwave Logic Inc (LWLG) 和Jasper Therapeutics Inc (JSPR) 均下跌6% 分别报4.35美元 3.45美元和2.43美元[4] - StableX Technologies Inc (SBLX) 和Galecto Inc (GLTO) 均下跌5% 分别报5.67美元和2.70美元[4]

公司业务定位 - 专注于转化肿瘤学研究领域 开发先进技术和服务以改善癌症治疗结果 [1] - 在肿瘤学领域与其他生物技术公司竞争 致力于提供创新性癌症研究和治疗解决方案 [1] 财务业绩表现 - 2026财年第一季度每股收益0.02美元 超出市场预期的-0.01美元 [2][6] - 季度营收约1400万美元 超过预估的1350万美元 [2][6] - 盈利收益率达4.12% 显示投资回报率处于合理水平 [5][6] 估值指标分析 - 市盈率约24.28倍 反映市场对公司盈利前景的信心 [4] - 市销率约2.57倍 企业价值与销售额比率约2.48倍 显示估值相对销售表现处于有利水平 [4] 财务结构状况 - 债务股权比率约1.62倍 表明公司对债务融资存在一定依赖 [5] - 流动比率约0.94倍 显示短期财务稳定性有待改善 [5] - 企业价值与经营现金流比率为负85.29倍 表明现金流生成能力面临挑战 [5] 管理层与市场关注度 - 首席执行官Robert Brainin和首席财务官David Miller参与季度业绩电话会议 阐述财务表现和战略方向 [3] - Pareto Ventures的George Marema和Craig-Hallum Capital Group LLC的Tollef Kohrman等知名机构参与者出席会议 显示市场对公司未来前景保持关注 [3]